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Bullous pemphigoid was ¢rst described by Lever in 1953
as a subepidermal blistering disease. Its immunohistolo-
gical features include dermal^epidermal junction se-
paration, an in£ammatory cell in¢ltrate in the upper
dermis, and basement membrane zone^bound autoan-
tibodies. These autoantibodies show a linear staining at
the dermal^epidermal junction, activate complement,
and recognize two major hemidesmosomal antigens,
BP230 (BPAG1) and BP180 (BPAG2 or type XVII col-
lagen). An IgG passive transfer mouse model of BP
was developed by administering rabbit antimurine
BP180 antibodies to neonatal mice. This model recapi-
tulates the key features of human bullous pemphigus.
Using this in vivo model system, several key cellular
and molecular events leading to the bullous pemphigus
disease phenotype were identi¢ed, including IgG bind-
ing, complement activation, mast cell degranulation,
and neutrophil in¢ltration and activation. Proteinases
and reactive oxygen species released by neutrophils
work together to damage the basement membrane
zone, causing dermal^epidermal junction separation.
Recent experimental data from human bullous pem-
phigus studies suggest that human bullous pemphigus
and its mouse IgG passive transfer model counterpart
may well share not only common immunohistological
features but also pathological mechanisms underlying
the development of this antibody-mediated disease.
Key words: animal model/autoimmune bullous disease/basement
membrane/hemidesmosome/in£ammation. J Investig Derma-
tol Symp Proc 9:41 ^46, 2004
BPAS AN INFLAMMATORY DISEASE
I
n 1953 Lever described the disease entity known as bullous
pemphigoid (BP) as a subepidermal bullous dermatosis
seen in elderly individuals (Lever, 1953). Light microscopic
examination of lesional/perilesional skin of BP shows sub-
epidermal vesiculation due to detachment of the epidermis
from the underlying dermis. In£ammatory cells, including eosi-
nophils, neutrophils, lymphocytes, and monocytes/macrophages,
are present in the upper dermis and bullous cavity, with eosino-
phils being the predominant cell type. Electron microscopic
analysis of BP lesional skin reveals a split at the level of the lami-
na lucida (the electron-lucent region immediately beneath the
basal keratinocyte) and decreased numbers of hemidesmosomes.
Intact and degranulating eosinophils and mast cells are seen in the
dermis.
Various in£ammatory mediators that can activate mast cells or
leukocytes have been identi¢ed in lesional skin and/or blister
£uids of BP patients, including (1) granular proteins derived from
degranulated leukocytes, such as eosinophil cationic protein
(ECP), eosinophil major basic protein (MBP), and neutrophil-de-
rived myeloperoxidase (MPO); (Baba et al, 1976; Czech et al, 1993;
Borrego et al, 1996) and (2) chemoattractants and cytokines, such
as C5a fragments (Diaz-Perez and Jordon, 1976), histamine
(Katayama et al, 1984), leukotriene B4 (Kawana et al, 1990),
IL-1,2,4,5,6,8,15, TNF-a, IFN-g, RANTES, and eotaxin
(reviewed by D’Auria et al, 1999; Wakugawa et al, 2000). Several
proteinases are also found in BP blister £uid, including plasmin,
collagenase, elastase, and 92-kDa gelatinase (Oikarinen et al, 1983;
Lauharanta et al, 1989; Baird et al, 1990; Gissler et al, 1992; Kramer
and Reinartz, 1993; Sthle-Bckdahl et al, 1994; Schaefer et al, 1996;
Verraes et al, 2001).
BPAS AN AUTOIMMUNE DISEASE
BP autoantibodies bind to the basement membrane zone (BMZ)
and activate complement (Jordon et al, 1967).These autoantibodies
are directed against two major hemidesmosomal antigens of 230
kDa (BP230 or BPAG1) and 180 kDa (BP180, BPAG2, or type
XVII collagen) (Stanley et al, 1981, 1984; Mutasim et al, 1985; Labib
et al, 1986). Both BP180 and BP230 have been cloned and charac-
terized at the molecular level (Stanley et al, 1988; Diaz et al, 1990;
Sawamura et al, 1991;Tanaka et al, 1991; Giudice et al, 1992). BP230
is an intracellular protein that localizes to the hemidesmosomal
plaque (Klatte et al, 1989; Tanaka et al, 1990; Ishiko et al, 1993) and
has signi¢cant homology with plectin and desmoplakins I and II
(Tanaka et al, 1991; Sawamura et al, 1991; Green et al, 1992). In con-
trast, BP180 is a transmembrane protein with a type II orientation
(Fig 1A). Its amino-terminal region localizes to the intracellular
hemidesmosomal plaque, and its carboxyl-terminal portion pro-
jects into the extracellular milieu of the BMZ (Giudice et al, 1992;
Hopkinson et al, 1992; Ishiko et al, 1993). The extracellular region
consists of 15 collagen domains separated from one another by
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noncollagen sequences. BP180 as a transmembrane antigen makes
it a preferred target for pathogenic autoantibodies in BP.
The humoral response in BP is polyclonal. Epitope-mapping
studies show that BP autoantibodies recognize multiple epito-
pes that cluster within the largest noncollagen domain (referred
to as NC16A) of the BP180 antigen (Giudice et al, 1993; Zillikens
et al, 1997). These BP180NC16A-speci¢c autoantibodies are
predominantly IgE and IgG isotypes and IgG1 and IgG4
subclasses (Bernard et al, 1990; Dopp et al, 2000; La⁄tte et al,
2001). The serum levels of autoantibodies to BP180NC16A are
correlated with the severity of BP (Haase et al, 1998; Dopp et al,
2000).
The majority of BP patients have autoreactive T cells that
recognize epitopes located in the extracellular region of BP180
(Budinger et al, 1998) and mainly in the NC16A domain
(Lin et al, 2000). These T lymphocytes express CD4 memory T
cell surface markers and exhibit aTH1/TH2 mixed cytokine pro-
¢le. These studies suggest that BP is a T cell^dependent, B cell^
dependent, and antibody-mediated skin autoimmune disease.
THE IGG PASSIVE TRANSFER MODEL OF BPAS AN IN
VIVO SYSTEM TO STUDY THE DISEASE
IMMUNOPATHOGENESIS
Blister formation in BP was thought to be an IgG autoantibody^
mediated process; however, previous attempts to demonstrate the
pathogenicity of patient autoantibodies were unsuccessful. BP
autoantibodies that react with an immunodominant and poten-
tially pathogenic epitope in NC16A of BP180 fail to cross-react
with the murine form of this autoantigen and thus cannot be as-
sayed for pathogenicity in a conventional passive transfer mouse
model (Fig 1A and 1B). As an alternative, my colleagues and I
generated rabbit polyclonal antibodies against a segment of the
murine BP180 protein homologous with the human BP180
NC16A (mBP180 NC14A), and passively transferred the puri¢ed
rabbit anti-mBP180 IgG into neonatal BALB/c mice. The injected
animals developed a blistering disease that closely mimicked hu-
man BP (Fig 1C) (Liu et al, 1993). Direct immuno£uorescence
analysis of the lesional/perilesional skin of the diseased mice re-
vealed in vivo deposition of rabbit IgG and mouse C3 at the base-
ment membrane. Routine histology of the lesional skin revealed
a DEJ separation and an extensive in£ammatory cell in¢ltration,
consisting of neutrophils, lymphocytes, and monocytes/macro-
phages, with neutrophils being the predominant cells (Fig 2A)
(Chen et al, 2002). Using mice de¢cient in these cells, we demon-
strated that mast cells, macrophages, and neutrophils play a role
in subepidermal blistering (Fig 2B). Epitope-mapping studies
revealed that pathogenic anti-mBP180 antibodies recognize a
9^12 amino acid stretch within the murine BP180 NC14A region
of the antigen (Liu et al, 1995a). Signi¢cantly, this epitope overlaps
the region of the human BP180 NC16A, which contains the
immunodominant epitopes recognized by human BP autoanti-
bodies.
The critical role of complement activation in experimental BP
is established by the following approaches: (1) C5-de¢cient mice
are resistant to experimental BP; (2) Balb/c mice pretreated with
cobra venom factor to deplete complement are resistant to experi-
mental BP; (3) F(ab0)2 fragments generated from the pathogenic
anti-mBP180 IgG cannot induce subepidermal blisters in C5-
Figure1. Human and mouse BP180. (A) Sequence comparison of hu-
man and murine BP180 proteins. A schematic representation of the struc-
tural organization of the human BP180 protein is shown at the top. The
orange arch designates the transmembrane domain. The red oval designates
the NC16A antigenic site recognized by BP autoantibodies. The COOH-
terminal extracellular region is made up of 15 interrupted collagen-like do-
mains (yellow rectangles). The box (in red) at the bottom shows the amino
acid sequence alignment of the human and murine BP180 within the BP
epitope. Identical residues are designated by double dots, and conservative
substitutions are marked by a single dot. An unusually high degree of se-
quence divergence is seen in the epitope region. (B) Characterization
of anti-BP180 antibody cross-species reactivity. Rabbit antimurine BP180
(a-mBP180) and rabbit antihuman BP180 (a-hBP180) NC16A domain anti-
sera were analyzed by immunoblotting (IB) using recombinant human
BP180 (H, lanes 1 and 3) or recombinant murine BP180 (M, lanes 2 and 4)
and indirect immuno£uourescence (IIF) using human (panels a and b) or
murine (panels c and d) skin sections. Anti-hBP180 autoantibodies react
with the recombinant human BP180 (lane 1) and human skin (panel a),
but fail to cross-react with recombinant mBP180 (lane 2) and mouse skin
(panel c). Conversely, anti-mBP180 antibodies react with mBP180 (lane 4)
and stain mouse skin (panel d), but do not bind hBP180 (lane 3) or human
skin (panel b). (C) Passive transfer of rabbit anti-mBP180 IgG. Neonatal
Balb/c mice were injected intradermally with rabbit antimurine BP180
IgG. After 24 hours, gentle friction elicits persistent epidermal wrinkling,
producing the ‘‘epidermal detachment’’ sign (panel a). Direct immuno£uor-
escence analysis shows deposition of anti-BP180 IgG (panel b) and murine
C3 (panel c) at the basement membrane zone. Histological examination of
lesional skin reveals dermal^epidermal junction separation with an in£am-
matory in¢ltrate (panel d).
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su⁄cient mice; and (4) C5-de¢cient mice reconstituted with C5a
become susceptible to experimental BP (Liu et al, 1995b). Further
studies reveal that the major function of complement activation is
to generate C5a that in turn activates mast cells (Fig 3A).
Extensive mast cell (MC) degranulation is seen in the lesional
skin of mice injected with pathogenic anti-mBP180 antibodies.
MC activation precedes neutrophil in¢ltration (Fig 3B), and
inhibition of MC degranulation blocks neutrophil in¢ltration
and subsequent blister formation. Furthermore, MC-de¢cient
mice are resistant to experimental BP and, when reconstituted
with MC, restore the pathogenic activity of anti-mBP180 IgG.
In addition, pathogenic anti-mBP180 antibodies also induce BP
skin lesions in MC-de¢cient mice reconstituted with neutrophils
(Fig 3C),TNF-a, or IL-8 (data not shown). These results suggest
that mast cells play a critical role in recruiting neutrophils (Chen
et al, 2001).
Figure 2. Cellular events in the IgG passive transfer model of BP.
(A) Quanti¢cation of in£ammatory cell recruitment in the dermis of mice
injected with pathogenic anti-BP180 IgG. Neonatal mice were injected i.d.
with pathogenic (black bars) or control IgG (gray bars).The skin sections at
the IgG injection site were obtained 24 hours postinjection and processed
to recover in¢ltrating cells. The di¡erent populations of in£ammatory cells
were identi¢ed by staining and £ow cytometry. The data shown are the
mean7SE. po0.05 and po0.01, Student t-test for paired samples.
PMN, neutrophils; Mf, macrophages; T, T lymphocytes; B, B lympho-
cytes; eos, eosinophils. (B) Clinical and histological examination of neona-
tal mice de¢cient in di¡erent in£ammatory cells injected with pathogenic
anti-mBP180 IgG. Neonatal mice were injected i.d. with anti-mBP180 IgG.
Twelve hours later, wild-type C57BL/6J (WT),T and B cell^de¢cient (T &
B(^)) mice developed subepidermal blisters. In contrast, mast cell^de¢cient
(MC(^)), macrophage-de¢cient (MF(^)), and neutrophil-de¢cient
(PMN(^)) mice injected i.d. with pathogenic IgG showed no evidence of
skin disease.
Figure 3. Functional relationship between complement, mast cells,
and neutrophils in the IgG passive transfer model of BP. Neonatal
mice were injected i.d. with pathogenic anti-mBP180 IgG and clinically
examined at di¡erent time points.The skin sections at each time point were
analyzed by mast cell (MC)-speci¢c staining (toluidine blue staining) for
MC identi¢cation and quanti¢cation and by myeloperoxidase (MPO) ac-
tivity assay for neutrophil in¢ltration. (A) Complement (C0) activation
causes MC degranulation. C5-su⁄cient mice (panel a) show extensive
MC degranulation at 2 hours and develop blisters at 12 hours post-injec-
tion. In contrast, C5-de¢cient mice (panel b) exhibit minimal MC degra-
nulation and no skin lesions. d, dermis. (B) Time course of MC
degranulation and neutrophil in¢ltration. MC degranulation reaches the
peak level at 1^2 hours after IgG injection (panel a), whereas PMN in¢ltra-
tion appears at 2 hours and reaches the peak level at 8 hours post-injection.
(C) Local reconstitution of neutrophils restores the pathogenic activity of
anti-mBP180 antibodies in MC-de¢cient mice. Injection of pathogenic
anti-mBP180 IgG causes BP in MC-su⁄cient, but not MC-de¢cient, mice.
MC-de¢cient mice reconstituted with neutrophils (by intradermal admin-
istration) injected with anti-mBP180 IgG develop BP. MC-de¢cient mice
pretreated intradermally with IL-8 or TNF-a also become susceptible to
experimental BP (data not shown).
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Neutrophil in¢ltration is a prerequisite for experimental BP,
and disease severity is directly correlated to the number of in¢l-
trating neutrophils (Liu et al, 1997). Mice depleted of neutrophils
are resistant to experimental BP. Blocking neutrophil in¢ltration
abolishes subepidermal blistering. Therefore, in¢ltrating neutro-
phils are the cells that directly cause tissue injury in the basement
membrane zone, leading to subepidermal blistering.
In¢ltrating neutrophils, upon activation through molecular in-
teraction between Fc of pathogenic anti-mBP180 IgG and Fc re-
ceptors on the cell surface of neutrophils, release several
proteolytic enzymes, including neutrophil elastase (NE) and ge-
latinase B (GB). Mice lacking NE or GB are resistant to experi-
mental BP (Liu et al, 1998, 2000). In vitro, although both GB and
NE are capable of degrading the recombinant BP180 protein,
only NE produces DEJ separation when incubated with skin sec-
tions (Sthle-Bckdahl et al, 1994; Liu et al, 2000) (Fig 4A). In vivo,
NE compensates for the lack of GB whereas GB cannot compen-
sate for NE de¢ciency in the development of BP. In addition, the
degradation of BP180 in vivo depends on NE activity (Fig 4B).
These ¢ndings demonstrate that GB acts upstream of NE.
Further dissection of this proteolytic event in experimental BP
reveals a functional relationship between GB and NE; GB pro-
teolytically inactivates a1-proteinase inhibitor, the physiological
inhibitor of NE. Unchecked NE then cleaves extracellular matrix
proteins, including BP180 antigen, resulting in DEJ separation
(Liu et al, 2000).
RELEVANCE OF THE IGG PASSIVE TRANSFER
MODELTO HUMAN BP
Experimental BP reproduces key characteristics of human BP at
the clinical, histological, and immunological levels (Liu et al,
1993). Since the development of the IgG passive transfer model
of BP in 1993, the pathogenic role of anti-BP180 antibodies
has been con¢rmed by other in vitro and in vivo studies.
BP180NC16A-speci¢c autoantibodies puri¢ed from human BP
sera induce dermal^epidermal separation in cryosections of hu-
man skin in the presence of neutrophils (Sitaru et al, 2002). Like
the rabbit anti-mBP180 IgG passive transfer model, rabbit antibo-
dies directed against the extracellular domain of hamster BP180
(NC16A region) trigger BP-like subepidermal blisters in neonatal
hamsters (Yamamoto et al, 2002).
Despite the similarities in the immunopathological features of
the experimental model of BP and the human disease, there is
one striking di¡erence. The in£ammatory in¢ltrate of early le-
sions in human BP shows large numbers of eosinophils. The ma-
jority of BP patients are eosinophil-rich with some patients
showing neutrophil-rich or pauci-in£ammatory pemphigoid
blisters. These di¡erent pathological presentations indicate that
BP is a heterogeneous disease and that blisters may be initiated
and sustained by multiple immunopathological mechanisms.
Some of these mechanisms require only pathogenic antibodies;
others depend on both pathogenic antibodies and in£ammatory
cells (eosinophils and neutrophils). Therefore, di¡erent BP pa-
tients may respond to a particular treatment di¡erently. In the
IgG passive transfer mouse model triggered by a well-de¢ned
IgG preparation, however, neutrophils are the predominant in-
£ammatory cell type. Time course studies did not uncover signs
of eosinophil recruitment into the injection site of the mice up to
24 hours after passive transfer of pathogenic anti-mBP180 IgG,
despite extensive subepidermal blistering observed by 12 hours
postinjection. Therefore, it is quite clear that in experimental BP,
eosinophils do not play an important role in the initial stages of
subepidermal blistering.
We cannot rule out the possibility of fundamental di¡erences
in the pathogenic mechanisms of human BP and mouse BP;
however, it remains quite possible that eosinophils are not di-
rectly involved, or play only an accessory role, in the initiation
of human BP. Interestingly, recent studies implicate neutrophils
as the possible disease^causing in£ammatory cells. In vitro DEJ se-
paration induced by human BP autoantibodies speci¢c for
BP180NC16A depends on neutrophils (Sitaru et al, 2002). This
study con¢rms the ¢ndings by Gammon and colleagues two
decades ago which showed that BP autoantibodies induce DEJ
Figure 4. Proteolytic events in the IgG passive transfer model of
BP. (A) Neutrophil elastase produces DEJ separation in mouse skin in vitro.
Neonatal mouse skin sections were incubated in medium alone (panel a),
with puri¢ed neutrophil elastase (NE) (panel b), or with gelatinase B (GB)
(panel c) at 371C for 24 hours and were examined by routine histology.
DEJ separation is seen in sections treated with NE but not GB or medium
control. Epidermis (e), dermis (d), blister vesicle (v), site of basal keratino-
cytes (arrow). (B) In vivo BP180 degradation depends on neutrophil elastase
(NE) activity. Neonatal wild-type (WT), NE-de¢cient (NE-), and GB-de-
¢cient (GB-) mice were injected i.d. with pathogenic IgG alone or with
neutrophils and were examined 12 hours after injection. The skin extracts
were analyzed by immunoblotting using the anti-mBP180 IgG. The wild-
type mice injected with pathogenic IgG develop BP blisters and both intact
and degraded BP180 are present in lesional skin extracts (lane 1). In con-
trast, NE-de¢cient mice injected with pathogenic IgG show no skin lesions
and no degraded BP180 was found in skin samples (lane 2). GB-de¢cient
mice locally reconstituted with 2.5 million GB-de¢cient (but NE-su⁄-
cient) neutrophils and then injected i.d. with pathogenic IgG develop BP,
and cleaved BP180 is detected in their lesional skin extracts (lane 3). In con-
trast, GB-de¢cient mice locally reconstituted with the same number of
NE-de¢cient (but GB-su⁄cient) neutrophils and then injected i.d. with
pathogenic IgG fail to develop BP, and extracts from their skin show only
intact BP180 (lane 4). As a negative control, wild-type mice injected i.d.
with normal IgG show no skin lesions and no degraded BP180 is seen in
skin extract samples (data not shown). mPMN: mouse neutrophils.
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separation in human skin sections only in the presence of both
leukocytes (mostly neutrophils) and complement (Gammon et
al, 1982). In addition, although human BP blister £uid has high
levels of both neutrophil elastase (NE) and gelatinase B (GB), its
degradation of BP180 depends on neutrophil elastase activity
(Verraes et al, 2001). These results con¢rm the ¢ndings from ex-
perimental BP and strongly suggest that NE plays a key role in
direct cleavage of BP180 and subepidermal blister formation in
human BP. In fact, neutrophil-predominant forms of BP have
been described in which eosinophils are absent in the in£amma-
tory cell in¢ltrate (Ackerman et al, 1997). It is worth noting that
most patient biopsies are obtained days or weeks after the onset
of disease activity. Eosinophil predominance may re£ect the
chronic stage of the in£ammatory reaction in BP.Taken together,
these ¢ndings strongly suggest that, as in the IgG passive transfer
model of BP, neutrophils may be responsible for subepidermal
blister formation in human BP. The exact role eosinophils play
in BP requires further investigation.
CONCLUSIONS
Recent experimental evidence strongly suggests that human BP
and mouse BP share not only a common disease phenotype but
also a common underlying immunopathogenesis. This model has
proved to be very useful in dissecting the anti-BP180 IgG-
mediated in£ammatory cascade in BP and could be used to test
new therapeutic strategies. Preclinical data demonstrate that
blocking any one of these steps can abolish the BP disease pheno-
type. Findings from the IgG passive transfer model of BP may
also have signi¢cant implications for cicatricial pemphigoid,
herpes gestationis, linear IgA bullous dermatosis, and lichen pla-
nus pemphigoides, all of which are autoimmune subepidermal
blistering disorders that have an anti-BP180 immune response
(Morrison et al, 1988; Bernard et al, 1992; Tamada et al, 1995; Zone
et al, 1998).
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